Featured Insight
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Poster Presentation: San Antonio Breast Cancer Symposium (SABCS) 2023
Gilead Sciences, Inc. will present new data at the San Antonio Breast Cancer Symposium (SABCS) 2023 supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients. Precision's research with Gilead Sciences on "Understanding Clinical Meaningfulness in Metastatic Breast Cancer Treatment Decision-Making" will be presented during Poster Session 1: Poster # PO1-10-06 on Wednesday, Dec. 6 at 12:00 PM. Co-authored by Meaghan Roach, Rozanne Wilson, Suepattra May-Slater, Melissa Maravic and Emily Freeman.
Short Courses: ISPOR EU 2023
Precision will be at ISPOR Europe November 12-15, 2023. Don't miss our two Short Courses.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
Webinar: Quantifying Health Equity Impact of Innovative Health Care Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join PRECISIONheor for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Article: Accelerated Approvals in Oncology: Benefits, Risks, and the Way Forward With Dr. Jason Mouabbi, Dr. Ross Maclean, and Michael Glover
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Article: Doubling Down on Deep Customer Insights to Inform Value Demonstration
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
On Demand: Quantifying Health Equity Impact of Innovative Healthcare Interventions
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health. Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.
On-Demand Webinar – A Novel Data and Analytics-Informed Approach to Launch Excellence
Launching a therapy has become increasingly challenging, with only 34% of launches meeting their year-one goals (Evaluate Pharma, McKinsey). In addition, launches have also become more complex, with additional stakeholders to consider as well as the careful navigation of siloed, enterprise-wide functions and dynamic, fragmented data solutions. Not surprisingly, the path to a successful launch can be very narrow.
Download Now: Precision September Events Calendar
Check out our September Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
From Volume-to-Value—The Critical Role of EHR
Today more than 90% of healthcare professionals are on an Electronic Health Records (EHR), and more than five hours of an eight-hour day are spent in the EHR. In parallel, life sciences companies have become increasingly aware of the ability to harness EHR data to solve for numerous challenges both in the pre-approval and post-commercialization arenas.
Hear From Key Stakeholders: The Future Treatment and Access Landscape for Cell & Gene Therapies Roundtable
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
MAPS Webinar: The Critical Role of Medical Affairs in Early R&D
In partnership with Precision VH, this webinar is a virtual panel discussion where experts will describe and debate the contributions that Medical Affairs can make to early R&D (preclinical through Ph-IIb).
New PRECISIONheor-led Study Examines Challenges in Capturing Economic Burden of Cancer
Congratulations to Suepattra May-Slater and the PRECISIONheor team for their contributions to a impactful study just published in the journal MDM Policy and Practice. The paper, entitled: "Estimating Productivity Loss from Breast and Non–Small-Cell Lung Cancer among Working-Age Patients and Unpaid Caregivers: A Survey Study Using the Multiplier Method" outlines the challenges in truly capturing the economic burden of cancer for both patients and their caregivers. The authors also suggest the need for more support in the workplace for these individuals, and a holistic approach to accounting for these impacts in treatment decision making.
Featured Expert: Alice Pressman
This month PRECISIONheor would like to highlight the newest addition to the team, Vice President Alice Pressman.
Value Assessment And Decision Making In The Face Of Uncertainty
There's been increasing interest in using Health Technology Assessment to guide coverage decisions and health policies. Recently, the COVID-19 experience has provided important lessons for value assessment of new interventions and its communication to stakeholders.
Self-Reported Health Care Resource Utilization in Clinical Trials
Real-world data are important sources within health care resource utilization (HCRU) research, but these databases often are repurposed for this use rather than custom designed. Some researchers are beginning to collect HCRU data within the context of clinical trials, with the intention to address research questions of interest, rather than relying solely on data salvaged from insurance claims or electronic health records.
Precision’s Stakeholder Insights
Using a multi-disciplinary, mixed methods approach to evidence generation, PRECISIONheor has an established track record of quantifying the value of treatment and communicating insights capturing the perspectives of key stakeholders.
PRECISIONheor Featured Real-World Evidence Publications
Want a glimpse at some of the insightful real-world evidence publications that PRECISIONheor experts have recently contributed to in order to help get life-saving treatments into the hands of patients that need them the most?
Featured Expert: Shannon Cope
This month PRECISIONheor would like to highlight the work and expertise of Vice President Shannon Cope.
On-Demand Webinar: Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations
Join us for "Methodological Borrowing versus Conceptual Blending: Reengineering Health Economics Processes with Modeling and Simulations," Featuring PRECISIONheor's Ross Maclean and Anuj Mubayi.
Conference: Virtual ISPOR 2021
Did you miss PRECISIONheor at Virtual ISPOR 2021? Find out more about what was presented at the conference and download our available posters here.
NCCN 2021 Virtual Annual Conference
Congratulations to PRECISIONheor’s Meaghan Roach MPH, Caroline Huber MPH, Suepattra May-Slater MPH, PhD, and Isha Desai MPH on the successful presentation of their poster "A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States" at NCCN 2021.
Virtual ISPOR Europe 2020
Congratulations to PRECISIONadvisors and PRECISIONheor for presenting more than a dozen posters and panels at Virtual ISPOR Europe 2020, 16 - 19 November, 2020.
HLTH Conference Video: The Science & Politics of Developing a COVID-19 Vaccine & Treatment
Congratulations to Precision Medicine Group Co-Founder and CEO Mark Clein on his moderated Point: Counterpoint panel at this year’s HLTH Conference.
On-demand Webinar: Social Determinants of Health–Perspectives From the Academic, Provider, and Research Community
Moderated by Precision's Ross Maclean, our distinguished panel of experts provide key insights on why social determinants of health (SDOH) are critical factors to inform today's treatment planning, care delivery, health policy, health outcomes and value.
